Nature Biomedical Engineering · 2017 · 515 citations · 23 references
MedicineHematologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsPlatelet ActivationPlatelet FunctionPlatelet PhysiologyActivationImmune Checkpoint Inhibitor TherapyPlatelet InhibitionPostoperative Thrombocytopenia
23
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations
Medicine, Oncology, Pharmacotherapy +13
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Hematoxylin and Eosin Staining of Tissue and Cell Sections
Andrew H. Fischer, Kenneth A. Jacobson, Jack Rose et al. · Cold Spring Harbor Protocols · 2008 · 2.1K citations